Both treatment with the two siRNAs in STP707 ... STP705 is the landmark therapy that provided the first positive cancer phase 2a for RNAi technology. In the phase 2 cutaneous squamous cell ...

He believes RNAi technology will disrupt medicine in the same way that monoclonal antibodies did when they were invented, changing treatment paradigms across several therapeutic areas. The first ...

Like the treatment for macular degeneration ... researchers have silenced more than a dozen known cancer-causing genes with RNAi. Yet, once again, most of this success has been with cell cultures ...

If all goes according to plan, the cancer is switched off and the ... warranted shutting down big pharma operations in the RNAi drug and treatment world? The answer, actually, is not completely ...

In this Innovation Spotlight, Kevin Fitzgerald, chief scientific officer at Alnylam Pharmaceuticals, discusses the RNAi approach to CVD treatment, recent clinical trial results, and the company’s ...

Researchers at the University of Ottawa may have cracked the code to harness both mRNA and RNAI-based therapies to improve the treatment of cancer, cardiovascular and other complex diseases.

Researchers at the University of Ottawa have figured out how to use mRNA and RNAI-based treatments to treat complex illnesses like cancer and heart disease. The success of COVID-19 vaccines has ...

Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, ...

The Gene Editing & Screening Core Facility (GES Core) brings together complementary technologies aimed at interrogating cancer biology and identifying molecular vulnerabilities of cancer cells. The ...

Silexion Therapeutics, known for its pioneering work in RNAi therapies ... for non-resectable pancreatic cancer. The company is committed to advancing cancer treatment, focusing on improving ...

“I think most people would argue ASO chemistry is good, but RNAi is the next generation.” The other Atalanta program on track to the clinic is a potential treatment for a rare form of epilepsy ...

This underscores SIL-204’s potential to enhance treatment regimens for pancreatic cancer and other KRAS-driven ... SIL-204 takes Silexion’s RNAi approach further by targeting a broader ...